ABIONYX Pharma
ISIN: FR0012616852 | Ticker: ABNX | LEI: 969500785J7VIC5YPC96
ABIONYX Pharma is a new-generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones
Thanks to its partners in research, medicine, its bioproduct suppliers and its shareholders, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.
Bât. D2 33-43 Avenue Georges Pompidou, 31130 Balma – France
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | FRA | |||
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | FRA | |||
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
27,914,274
IPOMarch 30, 2015
Stock exchange(s)Euronext Paris